首页 | 本学科首页   官方微博 | 高级检索  
   检索      

舌下含服卡托普利用于院前急救高血压急症的临床疗效及对患者血清sCD40L、sPECAM-1、PDGF-BB水平的影响
引用本文:孙宝存,董 科,朱爱华,王丽萍,康 康.舌下含服卡托普利用于院前急救高血压急症的临床疗效及对患者血清sCD40L、sPECAM-1、PDGF-BB水平的影响[J].现代生物医学进展,2019,19(7):1290-1292.
作者姓名:孙宝存  董 科  朱爱华  王丽萍  康 康
作者单位:唐山市人民医院急诊科;华北理工大学附属医院肾内科;唐山市工人医院皮肤科
基金项目:河北省医学科学研究重点课题(20181264)
摘    要:目的:探讨舌下含服卡托普利用于院前急救高血压急症的临床疗效及对患者血清可溶性CD40L(sCD40L)、可溶性血小板内皮细胞黏附分子1(sPECAM-1)、血小板衍生生长因子-BB(PDGF-BB)水平的影响。方法:选择2015年5月到2017年5月我院院前急救高血压急症患者65例作为研究对象,按照随机数表法分为观察组(n=35)和对照组(n=30)。对照组给予硝苯地平舌下含化治疗,观察组采用舌下含服卡托普利治疗。比较两组治疗后的疗效,治疗前后血清s CD40L、sPECAM-1、PDGF-BB水平、收缩压(SBP)、舒张压(DBP)、心率(HR)的变化及不良反应的发生情况。结果:治疗后,观察组临床疗效总有效率为94.29%,显著高于对照组(73.33%,P0.05);两组血清s CD40L、sPECAM-1、PDGF-BB、SBP、DBP及HR水平均较治疗前明显下降,且观察组以上指标均显著低于对照组(P0.05);观察组患者不良反应发生率为17.14%,明显低于对照组(56.67%,P0.05)。结论:舌下含服卡托普利用于院前急救高血压急症患者的临床效果显著优于硝苯地平舌下含化治疗,其可更有效改善患者血清sCD40L、sPECAM-1、PDGF-BB水平。

关 键 词:卡托普利  院前急救高血压急症  可溶性CD40L  可溶性血小板内皮细胞黏附分子1  血小板衍生生长因子-BB
收稿时间:2018/11/23 0:00:00
修稿时间:2018/12/18 0:00:00

Curative Efficacy of Undertongue Contains Captopril in the Treatment of Pre-hospital Emergency Hypertension and Its Effects on the Serum sCD40L, sPECAM-1 and PDGF-BB Levels
SUN Bao-cun,DONG Ke,ZHU Ai-hu,WANG Li-ping and KANG Kang.Curative Efficacy of Undertongue Contains Captopril in the Treatment of Pre-hospital Emergency Hypertension and Its Effects on the Serum sCD40L, sPECAM-1 and PDGF-BB Levels[J].Progress in Modern Biomedicine,2019,19(7):1290-1292.
Authors:SUN Bao-cun  DONG Ke  ZHU Ai-hu  WANG Li-ping and KANG Kang
Institution:Department of Emergency,Tangshan People''s Hospital, Tangshan, Hebei, 063000, China,Department of nephrology ,Affiliated Hospital of North China University of Technology, Tangshan, Hebei, 063000, China,Department of Emergency,Tangshan People''s Hospital, Tangshan, Hebei, 063000, China,Department of Emergency,Tangshan People''s Hospital, Tangshan, Hebei, 063000, China and Department of Dermatology ,Tangshan workers'' hospital, Tangshan, Hebei, 063000, China
Abstract:ABSTRACT Objective: To study the curative efficacy of undertongue contains captopril in the treatment of Pre-hospital emergency hypertension and its effects on the serum Soluble CD40L (sCD40L), Soluble platelet endothelial cell adhesion molecule 1 (specam-1) and Platelet derived growth factor -BB (pdgf-bb) levels. Methods: 65 cases of emergency patients with hypertension in our hospital from May 2015 to May 2017 were selected as the study subjects, they were divided into the observation group (n=35) and the control group (n=30) by the random number table method. The control group was treated with nifedipine sublingual inclusion, and the observation group was treated with captopril. The clinical efficacy, changes of serum sCD40L, specam-1, pdgf-bb, SBP, DBP, HR levels before and after treat- ment and the incidence of adverse reactions were compared between two groups. Results: After treatment, the total effective rate of ob- servation group was 94.29%, which was significantly higher than that of the control group (73.33%, P<0.05). The serum sCD40L, specam-1, pdgf-bb, SBP, DBP and HR levels of both groups after treatment were significantly lower than those before treatment, and the above indicators in the observation group were significantly lower than those in the control group (P<0.05). The incidence of adverse re- actions in the observation group was 17.14%, which was significantly lower than that in the control group (56.67%, P<0.05). Conclusion: The clinical effect of sublingual administration of captopril in prehospital emergency hypertension patients is significantly better than that of nifedipine sublingual administration, which can more effectively improve the serum sCD40L, specam-1 and pdgf-bb levels of patients.
Keywords:Captopril  Pre-hospital emergency hypertension  Soluble CD40L  Soluble platelet endothelial cell adhesion molecule 1  Platelet derived growth factor-BB
本文献已被 CNKI 等数据库收录!
点击此处可从《现代生物医学进展》浏览原始摘要信息
点击此处可从《现代生物医学进展》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号